Research programme: antimalarial compounds - Biomes

Drug Profile

Research programme: antimalarial compounds - Biomes

Alternative Names: Anti-malarials research programme - Biomes; Antimalarial compounds research programme - Biomes; Research programme: anti-malarials - Biomes; S-triazines

Latest Information Update: 16 Mar 2007

Price : $50

At a glance

  • Originator Biomes Pharmaceuticals
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 20 Jul 2000 This research is available for licensing (
  • 20 Jul 2000 New profile
  • 20 Jul 2000 Preclinical development for Malaria treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top